Part I: Creating Value from Cradle to Commercialization
Tuesday, October 7 2014
8:00 am – 10:00 am
Location: MassBio, 300 Technology Square, 8th Floor, Cambridge, MA
The Future of Biotech: Defining & Building Value in Healthcare
This is Part 1 of a three-part series.
Value creation is key to success in the life sciences industry. Biotechnology and pharmaceutical companies must be attuned to value drivers today more than ever. Stakeholders perceive value in a variety of ways and companies need to understand and balance the needs of all key stakeholder groups.
Hear perspectives from:
- Investors – Learn how investors assess value. Investors typically define value in terms of return on investment. This Forum will provide an opportunity to learn first-hand what value means to some investors.
- Providers - Learn how physicians responsible for prescribing new treatments to patients choose one product over another, how much benefit they see for their patients, and what value in the Rx world means to them. Some physicians steer clear of newly approved and launched products for the fear of high costs, limited improvement over existing therapies, dosing concerns, and higher incidence of unknown side effects.
- Payers - Learn how insurance companies assess value and how it correlates/interrelates with reimbursement.
- Patients/Patient Advocates – Understand value from the patient perspective. For a patient, the cost, side effects, and improvement in symptoms are some of the key factors.
Please join us to hear our panel of industry experts:
- Define value from different stakeholder view points and explain how it impacts company strategy, from business, IP, and reimbursement to marketing and messaging strategies;
- Discuss new business formation and operating paradigms such as more seed investments to validate concepts, as well as virtual biotech models, among others; and
- Address what biotech and pharma need to focus on to provide value and be relevant going forward.
- Timothy Coetzee, PhD, Chief Advocacy, Services and Research Officer, National Multiple Sclerosis Society
- Alan Crane, Partner & Entrepreneur, Polaris Partners
- Julia A. Gaebler, PhD, Vice President, Health Advances
- Paulina Hill, PhD, Senior Associate, Polaris Partners
- Ellen Lathi, MD, Medical Director, MS Center, St. Elizabeth’s Hospital
- Jill Lagace, MS Patient
- Pravin Chaturvedi, PhD, Chairman & CEO, IndUS Pharmaceuticals, Inc.
Pravin Chaturvedi, PhD, Chairman & CEO, IndUS Pharmaceuticals, Inc.
Dr. Chaturvedi is the Founder and Chairman of Boston-based IndUS Pharmaceuticals and a co-founder of Florida-based Oceanyx Pharmaceuticals and also serves as the Chief Executive Officer of both these organizations. He also serves as the Chief Scientific Officer of San Francisco-based Napo Pharmaceuticals. Previously he has served as the President and Chief Executive Officer of Boston-based Scion Pharmaceuticals. Dr. Chaturvedi remains or has previously served on the boards of IndUS, Oceanyx, FuelEd Schools, Cellanyx, Sindu Scion and TiE Boston. He also serves as an advisory board member to TFC Biosciences and is the Chair of the Research Advisory Council for the Health Sciences Center of West Virginia University. He is an adjunct faculty member at Georgetown Medical School.
Over his 25+ year career, Dr. Chaturvedi has participated or led the discovery and/or development activities for several new chemical entities (NCEs), culminating in the successful development and commercialization of seven new drugs that are currently marketed by various companies. Prior to his roles at Napo, IndUS, Oceanyx and Scion Pharmaceuticals, Dr. Chaturvedi, spent several years at Vertex Pharmaceuticals as the Head of Lead Evaluation. Prior to Vertex, he was in the preclinical group at Alkermes and he started his R&D career in the Product Development group at Parke-Davis/Warner-Lambert Company (now Pfizer). Dr. Chaturvedi holds a Ph.D. in Pharmaceutical Sciences from West Virginia University and a Bachelor’s in Pharmacy from the University of Bombay.
Timothy Coetzee, PhD, Chief Advocacy, Services and Research Officer, National Multiple Sclerosis Society
Dr. Timothy Coetzee is the Chief Advocacy, Services, and Research Officer of the National Multiple Sclerosis Society. In this capacity he is responsible for the Society’s mission delivery in the areas of state and federal advocacy, service and care management programs for people with MS, as well as the Society's research program, which funds more than 375 academic and commercial research projects around the world. Most recently, he served as President of Fast Forward, a venture philanthropy of the National Multiple Sclerosis Society where he was responsible for the Society's strategic funding of biotechnology and pharmaceutical companies as well as partnerships with the financial and business communities. Prior to Fast Forward, Dr. Coetzee led the Society's translational research initiatives on nervous system repair and protection in multiple sclerosis.
Dr. Coetzee is a member of the Institute of Medicine’s Forum on Neuroscience and Nervous System Disorders, and the study committee on Strategies for Responsible Sharing of Clinical Trial Data. He serves on the Board of Directors of the American Society of Experimental Neurotherapeutics, the National Institutes of Health National Advisory Neurological Disorders and Stroke Council, and he chairs the Integration Panel for the MS Research Program of the Department of Defense Congressionally Directed Medical Research Program.
Dr. Coetzee received his Ph.D. in molecular biology from Albany Medical College in 1993 and has since been involved in the field of multiple sclerosis research. He has been with the National MS Society since the fall of 2000.
Alan Crane, Partner & Entrepreneur, Polaris Partners
Alan joined Polaris Partners in 2002 and is a partner and entrepreneur focusing on building and investing in healthcare companies. He has served as founder and/or has played a significant role as chairman and CEO in building six Polaris companies.
Alan has co-founded and/or served as Chairman and CEO of Momenta Pharmaceuticals (NASDAQ: MNTA), Cerulean Pharma (NASDAQ:CERU), Visterra, Navitor Pharmaceuticals, XTuit Pharmaceuticals, and Arsia Therapeutics. In addition, Alan’s current and past boards include T2 Biosystems (NASDAQ: TTOO), Ocular Therapeutix (NASDAQ: OCUL), Sirtris Pharmaceuticals (NASDAQ: SIRT, acquired by Glaxo SmithKline), Adnexus Therapeutics (acquired by Bristol Myers Squibb), and Seventh Sense Biosystems. From 2002 to 2006, Alan was President and CEO of Momenta Pharmaceuticals (NASDAQ: MNTA). He joined Momenta as the fifth employee and built the company into a public company, creating an advanced and diversified pipeline, entering into two strategic collaborations with Novartis, and raising $275 million. The first product from Momenta’s pipeline achieved over $1B during its first year of sales.
Prior to Polaris, Alan was senior vice president of global corporate development at Millennium Pharmaceuticals, where he was responsible for leading Millennium’s strategic partnering, mergers and acquisitions, and licensing activities, generating over $2B in partner funding and acquiring 19 development stage products. Among these products was Velcade® which became the main basis of the company’s $9B acquisition by Takeda.
Prior to Millennium, Alan was a marketing executive at DuPont-Merck and a consultant with the Boston Consulting Group and Arthur D. Little.
Julia A. Gaebler, PhD, Vice President, Health Advances
Julia has accumulated over 15 years of experience in pharmacoeconomics, market access, health policy, and health services research in both the biopharma industry and academic research. A mathematical modeler by training, she applies Health Advances’ Market Access and Health Economic functional expertise across biopharma, medtech, diagnostics and HIT clients.
Immediately prior to joining Health Advances, Julia worked at Biogen Idec as Senior Director, Global Medical Outcomes Strategy where she provided strategic leadership and technical health outcomes expertise to ensure that medical product strategies and tactics anticipated the evolving demands of the global payer landscape. At Biogen she was also Director, Global Market Access where she built and managed a team of Health Economics and Outcomes Researchers (HEOR) responsible for payer value evidence development for the Company’s late stage development products, and led the global reimbursement and market access launches for TECFIDERA and FAMPYRA for Multiple Sclerosis. Julia has also held related positions at Amylin Pharmaceuticals and Hoffmann-La Roche where she supported payer and ‘Real World Evidence’ development for Phase II/III products in Diabetes, Obesity, HIV/AIDs and Hepatitis. In addition to her leadership positions in industry, Julia was Health Policy Researcher at the RAND Corporation where she applied her decision analytic methods to international and domestic health policy issues. Using a range of modeling and micro-costing methods, her research has explored the effectiveness and cost-effectiveness of health, medical, and diagnostic interventions for infectious diseases, diabetes and hypertension, and the transmission of antibiotic drug resistance.
Julia holds a BA from the University of Pennsylvania, a Masters in International Economics from Johns Hopkins University, and a Doctorate in Health Policy and Decision Analysis from Harvard University. She has held Adjunct Faculty positions at UCSD Division of Global Public Health and at the RAND Corporation and has published many articles on health technology assessment in journals such as Nature, Health Services Research, Diabetes Medicine, and Plos Medicine.